Results for tag: "Icatibant"

Icatibant is a type of cardiovascular drug used to treat acute attacks of hereditary angioedema (HAE). It is a synthetic peptide that works by blocking the action of bradykinin, a chemical that causes swelling in the body. Icatibant is administered as a subcutaneous injection and is available in both pre-filled syringes and auto-injectors. It is used to treat acute attacks of HAE in adults and children over the age of 12. Icatibant is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2011. It is currently marketed by Shire Pharmaceuticals, a subsidiary of Takeda Pharmaceuticals. Other companies involved in the market include CSL Behring, Pharming Technologies, and ViroPharma. Show Less Read more